Tier 4 — mechanistic

Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial

Szarvas Z, Reyff ZA, Peterfi A, Pinto CB, Owens CD, Kaposzta Z, Mukli P, Pinaffi-Langley ACDC, Adams CA, Muranyi M, Palacios FS, Hawkins B, Baur JA, Velez FS, Prodan CI, Kirkpatrick AC, Csiszar A, Ungvari Z, Balasubramanian P, Negri S, Tarantini S, Ding K, Buelow AA, Akbari A, Kellawan JM, Yabluchanskiy A
The Journal of pharmacology and experimental therapeutics 2025 392; 7; 103607

Bibliography

PubMed
PMID 40479886
PubMed Central
PMC13095416
DOI
10.1016/j.jpet.2025.103607
Funding
Indexed grant support includes CSRD VA, NIA NIH HHS. The complete funding declaration is not specified in the accessible abstract.
Competing interests
An author disclosed research/material support, consulting relationships and a patent involving NAD+ precursors, including relationships with Elysium Health and other companies.

Study snapshot

DesignOpen-label human intervention study
ModelHuman participants
Sample8 older adults with peripheral artery disease
InterventionOral NR without a placebo group
Duration4 weeks
EndpointsVascular function; cerebrovascular responses; cognition

What the study showed, in plain terms

The open-label pilot reported selected cognitive and cerebrovascular changes, with supporting experiments using participant serum.

Key findings

The open-label pilot reported selected cognitive and cerebrovascular changes, with supporting experiments using participant serum.

What this study can and cannot tell us

Eight participants and no control group leave practice effects and other explanations unresolved; these findings are not equivalent to the randomized walking trial.

Related papers in the corpus

Tier 2
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial
Lin Y et al. · GeroScience · 2025
Tier 2
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM et al. · Nature communications · 2024
Tier 2
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults
Martens CR et al. · Nature communications · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology